Transdermal Immunization with Microparticulate RSV-F Virus-like Particles Elicits Robust Immunity

No approved vaccines against respiratory syncytial virus (RSV) infections exist to date, due to challenges arising during vaccine development. There is an unmet need to explore novel approaches and a universal strategy to prevent RSV infections. Previous studies have proven the immune efficacy of virus-like particles (VLPs) consisting of RSV fusion (F) protein, yielding a highly immunogenic RSV-F VLP subunit vaccine. In this study, RSV-F VLP (with or without MPL (R)) was added to a polymer mix and spray-dried, forming microparticles. The formulations were transdermally administered in C57BL /6 mice to evaluate vaccine efficacy. The transdermal delivery of RSV-F VLP + MPL (R) was more effective in clearing lung viral loads and preventing weight loss after RSV challenge. At the cellular level, MPL (R) augmented the vaccine response in microparticulate form, which was evidenced by higher serum and lung antibody titers, and lower lung viral titers in the vaccinated groups. These preliminary results validate the effectiveness of the RSV-F VLP microparticulate vaccine via the transdermal route due to its potential to trigger robust immune responses.

Automated summary

There are currently no approved vaccines for RSV infections, but a study found that the transdermal delivery of RSV-F VLP microparticulate vaccine has the potential to trigger robust immune responses, effectively clearing lung viruses and preventing weight loss.